New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Core Insights - Aclaris Therapeutics has announced the potential of its investigational drug ATI-2138 to impact various human inflammatory diseases, supported by a new publication detailing its unique properties as a covalent inhibitor of ITK and JAK3 [1][2] Group 1: Drug Mechanism and Efficacy - ATI-2138 selectively inhibits ITK and JAK3, effectively blocking Th1, Th2, and Th17 cell activity, which are crucial in autoimmune and inflammatory diseases such as atopic dermatitis, alopecia areata, and vitiligo [2][4] - The publication describes in vitro and in vivo assessments of ATI-2138, including its efficacy in three animal models of inflammatory disease and safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) results from clinical trials [3][4] Group 2: Clinical Trial Results - In initial clinical trials, ATI-2138 was well tolerated at all tested doses, with no serious adverse events reported among participants [5] - The drug demonstrated dose- and time-dependent modulation of biomarkers associated with ITK and JAK3 activity in healthy human participants [5] Group 3: Company Overview - Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, aiming to address unmet medical needs in this area [6]